Heart failure · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in clinical heart failure Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Cardiomyopathy/heart failure primary cause of death Available‐case analysis · children with cancer receiving anthracyclines
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as (1) evidence of clinical congestive heart failure, (2) a reduction in LVEF as measured by MUGA to < 45% or (3) a decrease in LVEF as measured by MUGA of > 20 percent... · children with cancer receiving anthracyclines
Dexrazoxane may leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Clinical heart failure and subclinical myocardial dysfunction combined Defined as clinical heart failure (no definition provided) or subclinical myocardial dysfunction defined as decreased LVFS; however, it was stated that toxicity was graded acco... · children with cancer receiving anthracyclines
1 finding from 1 review
Has died · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall mortality (Reported as number of participants who died) compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Progression‐free survival · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response rate Defined as number of complete remissions (no definition of complete remission provided). Best‐case analysis · children with cancer receiving anthracyclines
It is very uncertain whether dexrazoxane changes tumour response rate Defined as number of complete remissions (no… compared with no cardioprotective intervention (very low certainty).
1 finding from 1 review
Tumour response rate Defined as number of complete responses (i.e. disappearance of active Hodgkin lymphoma (gallium negative, ≥ 70% decrease in the sum of the products of the perpendicular diameters of measurable lesions, and negative bone marrow... · children with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete responses (i.e.… compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Quality of life · children with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).
2 findings from 1 review
Secondary malignant neoplasms · children with cancer receiving anthracyclines
Dexrazoxane may leads to higher secondary malignant neoplasms Available‐case analysis compared with no cardioprotective intervention (low certainty).
1 finding from 1 review
Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Progression‐free survival · adults with cancer receiving anthracyclines
Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).
3 findings from 1 review
Partial response (partial or complete response) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete or partial… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Quality of life · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diabetic complications · People with diabetes mellitus (type 1 or type 2, mostly type 2) and periodontitis, at least 16 years of age
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects of treatment · People with diabetes mellitus (type 1 or type 2, mostly type 2) and periodontitis, at least 16 years of age
1 finding from 1 review
Resource implications (e.g. cost of incontinence management methods) · People with diabetes mellitus (type 1 or type 2, mostly type 2) and periodontitis, at least 16 years of age
The review found no eligible studies for this question.
1 finding from 1 review
Included studies did not report cost data. A brief economic commentary drew on four external economic evaluations (Smits 2020, Nasseh 2017, Choi 2020, Soloweij-Wedderburn 2017) suggesting potential cost…
0 studies
No studies found
Clinical attachment level (CAL) · People with diabetes mellitus (type 1 or type 2, mostly type 2) and periodontitis, at least 16 years of age
Periodontal treatment (subgingival instrumentation, with or without… led to lower clinical attachment level (CAL) compared with no active intervention/usual care; GRADE not reported.
1 finding from 1 review
MD -0.48 [-0.65, -0.31]
18 studies
GRADE not reported
Mean · health personnel
1 finding from 1 review